NCT06251947 - Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Ovarian CancerCervical Cancer

Interventions

DRUG

Efbemalenograstim Alfa

Efbemalenograstim Alfa is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Trial Locations (6)

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

Unknown

NOT_YET_RECRUITING

Xiangya Hospital, Central South University,, Changsha

NOT_YET_RECRUITING

Zhongda Hospital, School of Medicine, Southeast University, Nanjing

NOT_YET_RECRUITING

Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University,, Qingdao

NOT_YET_RECRUITING

Shanxi Provincial Cancer Hospital, Taiyuan

NOT_YET_RECRUITING

Zhejiang Cancer Hospital, Hangzhou